Company Profile LogoCytodel

Cytodel offers an early biopharma with technology platform that delivers therapeutic Abs to the inside of neurons.

Edit IconSuggest an Edit
Health Care
Pharmaceutical
Therapeutics
Biopharma

    Unlock insights on Cytodel and 2M+ companies now!

    About Cytodel

    CytoDel is a biopharmaceutical company that uses the tools of 21st-century molecular biology to produce recombinant derivatives of botulinum neurotoxin (BoNT) customized to specific applications. The technology allows CytoDel to manipulate the BoNT molecule, for next-generation BoNT products and into a drug delivery vehicle that can deliver therapeutic molecules to the inside of neurons. Biodefense is our top priority but CytoDel is developing programs to advance the treatment of nervous syste

    Company Highlights
    Year Founded

    2012

    icon-altEmployees

    4

    Location (HQ)

    USA

    Since Last Funding

    6 years 8 months

    Monthly Website Visitors

    457

    icon-altTotal Investment Amt

    $200K

    icon-altYoY Headcount Growth

    -32.79%

    Key Metrics

    Senior Hires

    NameLinkedin ProfilePositionDate Joined
    John Doehttps://www.linkedin.com/in/johndoeCEOCEO
    Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
    John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
    Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
    Get API access to complete private company database with growth metrics from 15 sources

    Similar Companies

    Health Care

    Biotechnology Research

    Pharmaceutical

    Therapeutics

    Biopharma